How I treat patients who mobilize hematopoietic stem cells poorly

LB To, JP Levesque, KE Herbert - Blood, The Journal of the …, 2011 - ashpublications.org
Abstract Transplantation with 2-5× 106 mobilized CD34+ cells/kg body weight lowers
transplantation costs and mortality. Mobilization is most commonly performed with …

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

ZD Crees, MP Rettig, RG Jayasinghe… - Nature medicine, 2023 - nature.com
Autologous hematopoietic stem cell transplantation (ASCT) improves survival in multiple
myeloma (MM). However, many individuals are unable to collect optimal CD34+ …

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

JF DiPersio, EA Stadtmauer… - Blood, The Journal …, 2009 - ashpublications.org
Abstract This phase 3, multicenter, randomized (1: 1), double-blind, placebo-controlled study
evaluated the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G …

[HTML][HTML] Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic …

D Sheppard, C Bredeson, D Allan, J Tay - Biology of Blood and Marrow …, 2012 - Elsevier
Collection of adequate hematopoietic stem cells (HSCs) is necessary for successful
autologous transplantation; however, a proportion of patients fail to collect the minimum …

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

N Flomenberg, SM Devine, JF DiPersio, JL Liesveld… - Blood, 2005 - ashpublications.org
Hematopoietic progenitor cells (HPCs) traffic to and are retained in the marrow through the
trophic effects of the chemokine stromal cell-derived factor-1α (SDF-1α) binding to its …

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

DG Maloney, AJ Molina, F Sahebi… - Blood, 2003 - ashpublications.org
The full potential of a graft-versusmyeloma effect after allogeneic hematopoietic cell
transplantation (HCT) for patients with multiple myeloma (MM) has not been realized …

Proposed definition of 'poor mobilizer'in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo …

A Olivieri, M Marchetti, R Lemoli, C Tarella… - Bone marrow …, 2012 - nature.com
Many lymphoma and myeloma patients fail to undergo ASCT owing to poor mobilization.
Identification of poor mobilizers (PMs) would provide a tool for early intervention with new …

[HTML][HTML] Transplanted CD34+ cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with …

PJ Stiff, I Micallef, AP Nademanee… - Biology of Blood and …, 2011 - Elsevier
Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for
patients with hematologic malignancies, yet the impact of transplanted CD34+ cell dose on …

Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen

CL Morris, E Siegel, B Barlogie… - British journal of …, 2003 - Wiley Online Library
The mobilization of peripheral blood stem cells was studied in 984 multiple myeloma
patients, including 106 patients aged≥ 70 years. Increasing age correlated inversely with …

Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma

MA Gertz, SK Kumar, MQ Lacy, A Dispenzieri… - Bone marrow …, 2009 - nature.com
We retrospectively analyzed outcomes of 716 patients with multiple myeloma who were
mobilized using CY and growth factor (n= 370) or growth factor alone (n= 346) before SCT …